Mar 25, 2026 12:19PM BTIG on Maze Therapeutics (MAZE): 'Stock Weakness Likely Due to Proteinuria Increases Seen in Two Diabetic Patienst

Mar 25, 2026 11:45AM Raymond James on Maze Therapeutics (MAZE): 'Sell-off on HORIZON Update Looks Like an Overreaction'

Mar 25, 2026 10:50AM Truist Securities on Maze Therapeutics (MAZE): observed activity in AMKD patients 'encouraging'

Mar 25, 2026 09:40AM Maze Therapeutics (MAZE) PT Raised to $110 at H.C. Wainwright

Mar 25, 2026 08:30AM Leerink Partners on Maze Therapeutics (MAZE): Ph2 results confirm 'best-in-class' profile

Mar 25, 2026 08:16AM Mizuho on Maze Therapeutics (MAZE): top-line data from Ph2 study shows 'best-in-class' potential

Mar 25, 2026 07:47AM Maze Therapeutics (MAZE) Misses Q4 EPS by 65c

Mar 25, 2026 07:39AM Enliven Therapeutics stock surges 28% on Merck-Terns deal

Mar 17, 2026 04:28PM Truist Securities Starts Maze Therapeutics (MAZE) at Buy

Mar 16, 2026 09:14AM Maze Therapeutics (MAZE) PT Raised to $58 at Wedbush

Mar 10, 2026 04:06AM Mizuho Starts Maze Therapeutics (MAZE) at Outperform

Feb 4, 2026 05:22PM Maze Therapeutics (MAZE) files mixed shelf

Jan 28, 2026 06:43AM H.C. Wainwright Reiterates Buy Rating on Maze Therapeutics (MAZE)

Dec 19, 2025 07:50AM Maze Therapeutics (MAZE) PT Raised to $46 at Guggenheim

Dec 18, 2025 04:10AM Maze Therapeutics (MAZE) PT Raised to $50 at Leerink Partners

Dec 4, 2025 06:51AM Maze Therapeutics (MAZE) PT Raised to $60 at H.C. Wainwright

Dec 4, 2025 05:27AM Wells Fargo Starts Maze Therapeutics (MAZE) at Overweight

Nov 13, 2025 04:06PM Raymond James Starts Maze Therapeutics (MAZE) at Outperform

Nov 6, 2025 07:01AM Maze Therapeutics presents drug data at kidney conference

Oct 17, 2025 04:20PM Maze Therapeutics (MAZE) files for 9.23M share offering by selling stockholders

Oct 3, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Maze Therapeutics (MAZE)

Sep 15, 2025 07:29AM Maze Therapeutics (MAZE) PT Raised to $50 at H.C. Wainwright

Sep 15, 2025 07:25AM Maze Therapeutics (MAZE) PT Raised to $34 at Guggenheim

Sep 12, 2025 07:32AM Maze Therapeutics (MAZE) PT Raised to $50 at H.C. Wainwright

Sep 11, 2025 03:56PM Maze Therapeutics (MAZE) PT Raised to $37 at BTIG

Sep 11, 2025 03:45PM Maze Therapeutics (MAZE) PT Raised to $34 at Leerink Partners

Sep 2, 2025 06:37AM BTIG Starts Maze Therapeutics (MAZE) at Buy

Aug 12, 2025 04:55PM Maze Therapeutics, Inc. (MAZE) Misses Q2 EPS by 15c

Jul 23, 2025 07:48AM H.C. Wainwright Starts Maze Therapeutics (MAZE) at Buy

May 15, 2025 05:23PM Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss of $1.15

Feb 25, 2025 06:29AM Leerink Partners Starts Maze Therapeutics (MAZE) at Outperform

Feb 25, 2025 05:30AM TD Cowen Starts Maze Therapeutics (MAZE) at Buy

Feb 25, 2025 12:59AM Guggenheim Starts Maze Therapeutics (MAZE) at Buy

Feb 25, 2025 12:58AM JPMorgan Starts Maze Therapeutics (MAZE) at Overweight

Feb 7, 2025 08:01AM Maze Therapeutics (MAZE) Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

Jan 31, 2025 12:21PM Maze Therapeutics (MAZE) Opens At $16.12, IPO Priced At $16

Jan 27, 2025 06:10AM Maze Therapeutics (MAZE) Files for 7.8M Share IPO at $15-$17/sh